Lassa Fever Vaccine Candidate Delivers Promising Phase 1 Results
A candidate vaccine against Lassa fever has shown a strong safety profile and encouraging immune responses in a phase 1 clinical trial, raising hopes for a long-sought preventive tool against the viral disease endemic in parts of West Africa. The vaccine, a replication-competent recombinant vesicular stomatitis virus-vectored formulation encoding the Lassa virus glycoprotein complex (rVSVΔG-LASV-GPC), was tested in 114 healthy volunteers in the United States and Liberia. Researchers reported no vaccine-related serious adverse events and no cases of hearing loss, a known complication of Lassa fever.

